Journal: Antibodies
Article Title: Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab
doi: 10.3390/antib13030071
Figure Lengend Snippet: Characterization of CARCIK-CD19 cells. ( A ) PBMCs were transfected with the CAR-MNZ and CAR-BG2 plasmids and expanded to CIK for 21 days. Total cell number at the end of the culture is shown, starting from the same number of cells in both cases (10 × 10 6 cells). ( B , C ) Percentage ( B ) and MFI ( C ) of CAR expression on CD3 + cells at the end of culture. ( D , E ) Immunophenotype was analyzed at the end of the cultures (day 21) by flow cytometry, including percentages of CD3 + , CD3 + CD4 + , CD3 + CD8 + , CD3 + CD56 + ( D ) and effector memory populations ( E ); ( F – H ) CAR + cells were purified at day 10–14 by immunoselection. Percentages of CAR + cells pre- and post-purification are shown. Representative flow cytometry histograms of CAR expression of non-purified and purified CARCIK-CD19 (respectively, CAR-MNZ 26.6%, 4588 MFI, and 97.1%, 4031 MFI; CAR-BG2 20.4%, 2641 MFI, and 96.8%, 3208 MFI). The results are the means and standard deviations of four to five experiments using different donors as starting material. (*: p < 0.05, ns: not significant).
Article Snippet: For in vitro functional assays, ten days after transfection the anti-CD19 CAR + cells were purified by labeling with the poly-histidine tagged recombinant human CD19 protein (His-rhCD19, Acro biosystems, Newark, DE, USA), followed by the anti-histidine FITC antibody and immunoselected through an anti-FITC magnetic beads separation column (Miltenyi Biotec, Bergisch, Gladbach, Germany).
Techniques: Transfection, Expressing, Flow Cytometry, Purification